Killing two birds with a stone: how to maximise benefit from metastasis-directed therapy and modern systemic treatment in oligometastatic hormone sensitive prostate cancer

Clin Exp Metastasis. 2022 Dec;39(6):841-843. doi: 10.1007/s10585-022-10187-2. Epub 2022 Oct 15.

Abstract

Recent findings confirmed benefit from metastasis-directed therapy in oligometastatic hormone sensitive prostate cancer (omHSPC). However, current landscape of systemic treatment suggests that patients could benefit, at the same time, from early initiation of intensified hormonal treatments. In this commentary, we performed an overview about literature evidence aiming to overcome this issue and provide the maximum clinical benefit to the patients, taking advantage of modern imaging (e.g. PSMA PET/CT), ablative local treatment and newest systemic therapies.

Trial registration: ClinicalTrials.gov NCT03449719 NCT05022914.

Keywords: Androgen deprivation therapy; Oligometastatic prostate cancer; PSMA PET/CT; Stereotactic ablative radiotherapy.

Publication types

  • Letter

MeSH terms

  • Hormones
  • Humans
  • Male
  • Positron Emission Tomography Computed Tomography* / methods
  • Prostatic Neoplasms* / drug therapy
  • Prostatic Neoplasms* / pathology

Substances

  • Hormones

Associated data

  • ClinicalTrials.gov/NCT03449719
  • ClinicalTrials.gov/NCT05022914